Yamamoto Toru, Inoue Takutoshi, Kishimoto Naotaka, Seo Kenji
Division of Dental Anesthesiology, Faculty of Dentistry & Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan.
Department of Anatomy, Teikyo University School of Medicine, Tokyo, Japan.
J Dent Anesth Pain Med. 2025 Feb;25(1):15-22. doi: 10.17245/jdapm.2025.25.1.15. Epub 2025 Jan 22.
This review aims to evaluate the safety of remimazolam for intravenous sedation during dental treatment and oral surgery. The protocol was registered in the Open Science Framework (registration DOI: 10.17605/OSF.IO/RFPSZ), and reporting followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR). Literature searches and screenings were conducted using PubMed and the Cochrane database, with additional records manually reviewed from various sources. The selected studies, published in English, investigated the safety of remimazolam for sedation in dental and oral surgery. An initial search identified 20 studies, of which five prospective studies met the inclusion criteria. All included studies used an initial bolus administration of remimazolam. Primary outcomes assessed were the sedation success rate, incidence of adverse effects, onset time, awakening time, recovery time, and postoperative side effects. This scoping review indicates that all studies validated the superiority of remimazolam over other sedatives for dental treatment and oral surgery. The development and research of innovative technologies to reduce dental pain and anxiety presents opportunities for interdisciplinary collaboration and improved patient care in dental practice. Future clinical studies should focus on determining the optimal timing for additional dosing and discontinuation when remimazolam is administered continuously.
本综述旨在评估瑞马唑仑在牙科治疗和口腔外科手术中用于静脉镇静的安全性。该方案已在开放科学框架中注册(注册号DOI:10.17605/OSF.IO/RFPSZ),报告遵循系统评价和Meta分析扩展的范围综述优先报告项目(PRISMA-ScR)。使用PubMed和Cochrane数据库进行文献检索和筛选,并手动查阅来自各种来源的其他记录。所选的以英文发表的研究调查了瑞马唑仑在牙科和口腔外科手术中镇静的安全性。初步检索确定了20项研究,其中5项前瞻性研究符合纳入标准。所有纳入研究均采用瑞马唑仑初始推注给药。评估的主要结局包括镇静成功率、不良反应发生率、起效时间、苏醒时间、恢复时间和术后副作用。本范围综述表明,所有研究均证实瑞马唑仑在牙科治疗和口腔外科手术中优于其他镇静剂。开发和研究减轻牙科疼痛和焦虑的创新技术为牙科实践中的跨学科合作和改善患者护理提供了机会。未来的临床研究应专注于确定连续使用瑞马唑仑时额外给药和停药的最佳时机。